Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis
Authors' conclusion
This study compared the cardiovascular benefits of different GLP-1RAs, including reductions in cardiovascular events and improvements in multiple cardiovascular risk factors. However, due to limitations in the quantity and quality of the included studies, the conclusions should be interpreted with caution. Future large-scale, high-quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients.
Study context
- Population
- Published randomized controlled trials (RCTs) comparing GLP-1 RAs to placebo or other GLP-1 RAs; PubMed, Embase, Cochrane Library and Web of Science to December 15, 2024; 14 different GLP-1 RAs
- Participants
- 144,782 participants156 studies
- Comparison
- GLP-1 RAs vs placebo or other GLP-1 RAs
- Outcome
- Cardiovascular events and risk factors
Methodological detailsCochrane Risk of Bias tool, Confidence in Network Meta-Analysis (CINeMA)
- Cochrane Risk of Bias tool
- CINeMA
Pooled result
As reported in the abstract
- Efpeglenatide most effective in reducing MACE
- Oral semaglutide showed more significant advantages in reducing all-cause and cardiovascular mortality
- Orforglipron excelled in glycaemic control and weight reduction
- SC-Semaglutide greatest efficacy in lowering systolic and diastolic blood pressure
- Liraglutide greatest efficacy in lowering total cholesterol; Noiiglutide in TG; Taspoglutide in LDL-C; no GLP-1 RA in HDL-C
- Low heterogeneity
Safety
- GLP-1 RAs did not significantly increase the incidence of adverse events
- Orforglipron and Taspoglutide significantly increased gastrointestinal adverse events vs placebo
Original publication
Comparison of the efficacy and safety of GLP ‐1 receptor agonists on cardiovascular events and risk factors: A review and network meta‐analysis. Diabetes Obes Metab. Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →